Hazlett, Burt & Watson’s Iovance Biotherapeutics IOVA Stock Holding History

Hazlett, Burt & Watson’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Hold	100	–	–	﹤0.01%	943
2026 Q1	$0	Hold	100	–	–	﹤0.01%	936
2025 Q4	$0	Hold	100	–	–	﹤0.01%	937
2025 Q3	$0	Hold	100	–	–	﹤0.01%	894
2025 Q2	$0	Hold	100	–	–	﹤0.01%	825
2025 Q1	$0	Hold	100	–	–	﹤0.01%	812
2024 Q4	$1K	Hold	100	–	–	﹤0.01%	731
2024 Q3	$1K	Hold	100	–	–	﹤0.01%	702
2024 Q2	$1K	Hold	100	–	–	﹤0.01%	679
2024 Q1	$1K	Hold	100	–	–	﹤0.01%	679
2023 Q4	$1K	Sell	100 -47	-32%	-$246	﹤0.01%	654
2023 Q3	$0	Hold	147	–	–	﹤0.01%	729
2023 Q2	$1K	Hold	147	–	–	﹤0.01%	646
2023 Q1	$1K	Hold	147	–	–	﹤0.01%	593
2022 Q4	$1K	Hold	147	–	–	﹤0.01%	593
2022 Q3	$1K	Hold	147	–	–	﹤0.01%	597
2022 Q2	$2K	Buy	147 +47	+47%	+$616	﹤0.01%	561
2022 Q1	$2K	Buy	+100	New	+$1.55K	﹤0.01%	561

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Hazlett, Burt & Watson's IOVA Position: Q2 2026 in Review

Hazlett, Burt & Watson held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 100 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #943.

Hazlett, Burt & Watson first reported a position in IOVA in Q1 2022 and has held it in 18 quarters since. The position peaked at $2K in Q2 2022. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Hazlett, Burt & Watson held 100 shares of Iovance Biotherapeutics worth $0 as of Q2 2026.
Hazlett, Burt & Watson left its Iovance Biotherapeutics share count unchanged in Q2 2026.
Iovance Biotherapeutics made up ﹤0.01% of Hazlett, Burt & Watson's portfolio in Q2 2026, its #943 holding.
Hazlett, Burt & Watson first reported a position in Iovance Biotherapeutics in Q1 2022 and has held it in 18 quarters since.
Hazlett, Burt & Watson's Iovance Biotherapeutics position peaked at $2K in Q2 2022.
293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q2 2026, filed 30 Jul 2026.